Research finds lower empathy in major depressive disorder patients, indicating neuropeptides may serve as biomarkers.
Major depressive disorder (MDD) is a common disorder influenced by biopsychosocial factors. There is conflicting and insufficient evidence regarding the role of neuropeptides such as Orexin-A and Oxytocin (OCT) and its association with empathy in MDD. This study aimed to address this question which is not only important for a better neurobiological understanding but could also lead to novel biomarkers. Sixty-nine antidepressant-free patients (48 females, 21 males) diagnosed with MDD according to DSM-5 criteria and 32 healthy controls (19 females, 13 males) were included. Serum Orexin-A and OCT levels were measured, and empathy and depression were assessed using the Basic Empathy Scale and the Hamilton Depression Rating Scale. Patients showed lower cognitive empathy than controls (Z = 4.161, p < 0.001), with significant differences only in females. Emotional and total empathy scores did not differ between groups. Patients had higher serum OCT levels (Z = 1.989, p = 0.047), while Orexin-A levels showed no clear group differences. Longer illness duration and more depressive episodes were modestly associated with higher emotional and total empathy. OCT levels showed a weak positive association with cognitive empathy. Lower cognitive empathy and elevated OCT levels may relate to depressive pathology, but further studies are needed to clarify these relationships.
No takes yet. Share an insight, caveat, or question.
Erdem et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: